文献速递甲状腺疾病

淋巴细胞性甲状腺炎与携带突变BRAF的甲状腺乳头状癌的关联:系统综述与Meta分析

The Association between Lymphocytic Thyroiditis and Papillary Thyroid Cancer Harboring Mutant BRAF: A Systematic Review and Meta-Analysis.
PubMed 文献 · Thyroid · 2024-07-18

该系统综述与Meta分析检索PubMed、Embase和Web of Science Core Collection从2010年至2023年6月的观察性研究,纳入47项研究,其中39项共28143例患者显示,淋巴细胞性甲状腺炎(LT)存在时甲状腺乳头状癌(PTC)携带BRAF突变的比值显著降低(OR 0.53,95%CI 0.48-0.58,p<0.00001)。PTC伴LT与更好的预后因素相关,但PTC复发不受BRAF或LT影响。

要点

  • LT存在时PTC-BRAF的比值显著低于无LT时(OR 0.53,95%CI 0.48-0.58,p<0.00001)。
  • PTC-BRAF患者中央区颈部淋巴结病、PTC>1 cm、甲状腺外扩展、AJCC 3-4期和多灶性的汇总OR分别为1.54、1.14、1.66、1.53和1.24(对比野生型PTC)。
  • PTC伴LT患者中央区颈部淋巴结病、PTC>1 cm、甲状腺外扩展和AJCC 3-4期的汇总OR分别为0.64、0.83、0.71和0.84(对比无LT的PTC)。

核心结论

  • LT存在时PTC-BRAF的比值显著低于无LT时。
  • PTC伴LT(无论BRAF状态)与更好的预后因素显著相关。
  • 需要进一步研究评估LT是否抑制PTC-BRAF,以及这是否与晚期甲状腺癌中免疫治疗的作用相关。

研究设计与样本

  • 系统综述与Meta分析,检索PubMed、Embase和Web of Science Core Collection从2010年至2023年6月发表的观察性研究,纳入成人PTC患者。
  • 检索策略获得47项有相关数据的研究,其中39项研究共28143例患者纳入LT与PTC-BRAF的比值分析。
  • 研究注册于PROSPERO(CRD42023437492)。

主要发现

  • 39项研究共28143例患者显示,LT存在时PTC-BRAF的比值显著低于无LT时(OR 0.53,95%CI 0.48-0.58,p<0.00001)。
  • 在PTC-BRAF患者中,对比野生型PTC(无论LT状态),中央区颈部淋巴结病、PTC>1 cm、甲状腺外扩展、AJCC 3-4期和多灶性的汇总OR分别为1.54(95%CI 1.16-2.04)、1.14(95%CI 0.82-1.58)、1.66(95%CI 1.40-1.97)、1.53(95%CI 1.35-1.75)和1.24(95%CI 1.11-1.40)。
  • 在相同研究中,对比无LT的PTC(无论BRAF状态),PTC伴LT患者中央区颈部淋巴结病、PTC>1 cm、甲状腺外扩展和AJCC 3-4期的汇总OR分别为0.64(95%CI 0.51-0.81)、0.83(95%CI 0.73-0.95)、0.71(95%CI 0.58-0.86)和0.84(95%CI 0.75-0.94)。
  • PTC复发不受BRAF或LT影响,汇总OR分别为1.12(95%CI 0.66-1.90,p=0.67)和0.60(95%CI 0.28-1.30,p=0.20)。
  • 在此有限数据集中,以风险比表示的复发结果相似。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Papillary thyroid cancer (PTC) and lymphocytic thyroiditis (LT) co-occur with a prevalence of about 30%. PTC harboring BRAFV600E (PTC-BRAF) confers a worse prognosis, but it is unclear if LT alters prognostic features and recurrence of PTC. Objective: We compared the prevalence of PTC-BRAF with and without LT. The risk of adverse pathological features in (i) PTC in the presence and absence of BRAF mutation, irrespective of LT status, was compared to (ii) PTC in the presence and absence of LT, irrespective of BRAF status. Methods: We searched PubMed, Embase, and Web of Science Core Collection for observational studies published from 2010 to June 2023 on adult patients with PTC. The search strategy yielded 47 studies with relevant data. Data of baseline characteristics, clinicopathological features, and the quality assessment tool were extracted by two reviewers. The study was registered with PROSPERO (CRD42023437492). Results: Of the 47 studies, 39 studies with a total cohort of 28 143, demonstrated that the odds of PTC-BRAF were significantly lower in the presence of LT compared to its absence (odds ratio [OR] 0.53, 95% confidence interval [CI]: 0.48-0.58, p < 0.00001). In PTC-BRAF patients, there was a positive association of central neck nodal disease (CNND), PTC > 1 cm, extra-thyroidal extension, American Joint Committee on Cancer (AJCC) Stage 3-4, and multifocality with pooled ORs of 1.54 (95% CI: 1.16-2.04), 1.14 (95% CI: 0.82-1.58), 1.66 (95% CI: 1.40-1.97), 1.53 (95% CI: 1.35-1.75), and 1.24 (95% CI: 1.11-1.40) respectively, compared to wild-type PTC, irrespective of LT status. In the same studies, PTC with LT patients had lower pooled ORs of 0.64 (95% CI: 0.51-0.81) for CNND, 0.83 (95% CI: 0.73-0.95) for PTC > 1 cm, 0.71 (95% CI: 0.58-0.86) for ETE, 0.84 (95% CI: 0.75-0.94) for AJCC Stage 3-4 compared to PTC without LT, irrespective of BRAF status. PTC recurrence was not affected by BRAF or LT, with pooled ORs of 1.12 (95% CI: 0.66-1.90, p = 0.67) and 0.60 (95% CI: 0.28-1.30, p = 0.20) respectively. Similar results were seen with recurrence expressed as hazard ratio in this limited data-set. Conclusion: The odds of PTC-BRAF are significantly lower in the presence of LT than without. PTC with LT, irrespective of BRAF status, was significantly associated with better prognostic factors. Further studies are required to evaluate if LT inhibits PTC-BRAF, and whether this is relevant to the role of immunotherapy in advanced thyroid cancer.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Perampalam S, Wu K, Gild M, et al. The Association between Lymphocytic Thyroiditis and Papillary Thyroid Cancer Harboring Mutant BRAF: A Systematic Review and Meta-Analysis. Thyroid. 2024. PMID: 38940753. doi:10.1089/thy.2024.0142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。